Arginase Deficiency Market By Diagnosis(Genetic Testing, New-born Screening, And Others), By Treatment(Nitrogen-Binding Adjunctive, Nitrogen Scavenger Drugs, And Others), By End-User(Hospitals, Specialty Clinics, And Others), By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast 2023-2032
-
37666
-
June 2023
-
188
-
-
This report was compiled by Correspondence Linkedin | Detailed Market research Methodology Our methodology involves a mix of primary research, including interviews with leading mental health experts, and secondary research from reputable medical journals and databases. View Detailed Methodology Page
-
Quick Navigation
Report Overview
Arginase Deficiency Market size is expected to be worth around USD 152.3 Mn by 2032 from USD 102 Mn in 2022, growing at a CAGR of 4.2% during the forecast period from 2023 to 2032.
The research report on the Global Arginase Deficiency Market provides a comprehensive and exhaustive analysis of various market aspects, including market size, share, expansion, and key market trends. It identifies and analyzes key manufacturers, distributors, and suppliers, as well as the leading manufacturers, distributors, and suppliers. The report explores regional market segments in North America, Europe, Asia-Pacific, and Latin America beyond the surface. In doing so, it reveals growth opportunities that are unique to each market. In addition, it investigates the competitive landscape and provides a comprehensive analysis of the main market participants.
Arginase Deficiency, an extremely rare genetic metabolic disorder, affects a tiny fraction of the world's population, roughly one in one million individuals. This enigmatic disorder is caused by a deficiency in the enzyme arginase, an essential component of the urea cycle responsible for the body's ammonia elimination. As a result, an excessive accumulation of toxic ammonia wreaks devastation in the bloodstream, leading to neurodegenerative complications and other severe symptoms. Importantly, this disorder follows an autosomal recessive pattern of inheritance.
Understanding the importance of the Global Arginase Deficiency Market is crucial, as it caters to the critical requirements of those afflicted with this disorder. As appropriate care and treatment can alleviate symptoms and improve patients' overall quality of life, their provision becomes crucial. Numerous diagnostic instruments, therapeutic interventions, and medications are available on the market to aid in the accurate diagnosis and subsequent treatment of the disorder. This multifaceted approach not only enables patients to effectively manage their symptoms but also prevents the disorder from progressing to life-threatening stages.
Pharmaceutical firms are heavily investing in the Global Arginase Deficiency Market, conducting rigorous clinical trials and developing novel treatments and medications. Concurrently, efforts are being made to strengthen research and development initiatives aimed at improving diagnostic instruments and expanding our understanding of the disorder's underlying causes and mechanisms. Numerous hospitals and healthcare providers have incorporated arginase deficiency remedies and medications seamlessly into their comprehensive service offerings.
The growth trajectory of the Global Arginase Deficiency Market is supported by a confluence of factors, such as increased awareness of the disorder, notable advancements in diagnostic and treatment approaches, substantial investments by industry leaders, and a surge in partnerships and collaborations. Unquestionably, the development of this market is driven by an unwavering commitment to provide improved care and treatment, ultimately enhancing the quality of life for people with arginase deficiency and their families.
Driving Factors
Increased Awareness
The growing awareness of arginase deficiency among healthcare professionals, patients, and the general population has been a major factor in the market's expansion. Improved comprehension of the disorder and its symptoms has resulted in earlier diagnosis, prompt intervention, and enhanced management of the condition.
Advancements in Diagnostic Methods
Diagnostic procedures for arginase deficiency have undergone a revolution due to technological advancements. Innovative and precise diagnostic tools, such as genetic testing and biomarker analysis, have facilitated early detection and accurate diagnosis of the disorder. These innovations have contributed to enhanced patient outcomes and a rise in market demand for diagnostic solutions.
Advances in Treatment Approaches
Significant progress has been made in the development of arginase deficiency treatment approaches. Innovative therapies, such as enzyme replacement therapy and gene therapy, have demonstrated promise in preclinical and clinical trials. These innovations have created new avenues for effective treatment and contributed to the market's expansion.
Strategic Investments
Pharmaceutical companies, research institutions, and other healthcare industry leaders have made substantial investments in the Global Arginase Deficiency Market. These investments are intended to support research and development, clinical trials, and the commercialization of new treatments. These investments not only spur innovation but also foster a favorable market environment for expansion.
Collaborative Efforts
The market has been driven forward by collaboration among various stakeholders, including pharmaceutical companies, healthcare providers, patient advocacy organizations, and research institutions. Knowledge sharing, resource aggregation, and the development of comprehensive care models are facilitated by collaborative initiatives. These collaborative efforts contribute to the enhancement of patient care, the expansion of treatment options, and the expansion of the market.
Regulatory Support
Supportive regulatory frameworks and favorable reimbursement policies have also contributed to the development of the Global Arginase Deficiency Market. Regulatory agencies play a crucial role in accelerating the approval process for innovative therapies and assuring patient access to these treatments. This regulatory support encourages investment and fosters an environment conducive to market growth.
Although arginase deficiency is a rare disorder, the rising global population and enhanced diagnostic capabilities have led to an increase in the number of cases being diagnosed. The expanding patient population drives demand for diagnostic instruments, treatment options, and supportive care services, thereby driving market expansion.
Restraining Factors
Limited Treatment Options
Arginase deficiency is a rare autosomal recessive disorder caused by a lack of the enzyme arginase, which causes toxic levels of arginine to accumulate in the blood and urine. Arginase deficiency symptoms can range from moderate intellectual disability to severe neurological dysfunction, spasticity, and seizures, which can lead to significant physical and developmental delays. There are currently no FDA-approved therapies for arginase deficiency, and patients are frequently treated with palliative care to alleviate their symptoms.
Diagnosis Challenges
The symptoms of arginase deficiency are similar to those of other conditions, and the disease's rarity means that physicians may not always consider it as a potential cause of a patient's symptoms. As a result, healthcare providers frequently take a considerable amount of time to diagnose arginase deficiency, making it difficult to develop effective treatment plans and manage the progression of the disease.
Disease Variability
Arginase deficiency is a highly variable disease, with symptoms ranging from mild to severe, and this variability can make it difficult to develop treatment options that are effective for all patients. In addition, the rarity of this disease has limited the number of research studies conducted, and additional research is required to obtain a thorough understanding of its underlying mechanisms in order to develop targeted treatments.
Research Funding Limitations
Due to the small number of arginase deficiency cases worldwide, there is limited funding for research studies and drug development. As a result, conducting clinical trials, devising treatment options, and obtaining regulatory approval pose significant obstacles for researchers. This results in limited access to effective remedies for patients with Arginase Deficiency.
Diagnosis Analysis
With the Genetic Testing Segment dominating the market, the Global Arginase Deficiency Market has been on an upward trajectory. In recent years, genetic testing has become widespread, not only for diagnosing genetic disorders but also for assessing the dangers of certain health conditions. In the coming years, it is anticipated that the Genetic Testing Segment will register a substantial growth rate.
The increasing prevalence of genetic disorders worldwide and the need for early diagnosis is one of the primary drivers of this expansion. Arginase Deficiency is an uncommon genetic disorder that inhibits the body's ability to break down arginine, resulting in the accumulation of toxic substances.
As genetic testing technology has advanced, it has become simpler to diagnose Arginase Deficiency early, resulting in improved patient outcomes. This has resulted in an increase in demand for genetic testing services, which has fueled the expansion of the Genetic Testing Segment of the Arginase Deficiency Market.
Treatment Analysis
With an anticipated high growth rate over the next few years, the Nitrogen Binding Adjunctive Segment dominates the Global Arginase Deficiency Market. Nitrogen-Binding Adjunctive therapy is an effective treatment for Arginase Deficiency because it aids in the elimination of the disease-related accumulation of deleterious substances.
The economic prosperity of emerging economies has been a significant factor in the segment's expansion. With the rise of the middle class in these nations, an increasing number of individuals have access to healthcare services and are pursuing treatment for genetic disorders. This has substantially contributed to the growth of the segment by increasing demand for Nitrogen-Binding Adjunctive therapy.
Consumer trends and attitudes toward Nitrogen-Binding Adjunctive therapy have also contributed to the segment's expansion. Patients are taking a more active role in managing their health and are pursuing affordable, effective treatments. Nitrogen-Binding Adjunctive therapy has proven to be a cost-effective option for treating Arginase Deficiency, resulting in an increase in demand for the therapy.
End-User Analysis
With a high projected growth rate in the coming years, the Hospitals Segment dominates the Global Arginase Deficiency Market. Hospitals are essential providers of medical care for individuals with genetic disorders, such as Arginase Deficiency.
The economic prosperity of emerging economies has been a significant factor in the segment's expansion. As a result of rising incomes and greater health consciousness, more people in emerging economies are searching out healthcare services, resulting in a rise in the demand for hospital services for Arginase Deficiency patients.
Consumer attitudes and behavior toward hospital services have also contributed to the segment's expansion. Patients are becoming more proactive in managing their health, and they seek out hospitals with a reputation for providing high-quality medical care. This has increased the demand for hospitals specializing in the treatment of genetic disorders such as Arginase Deficiency.
Key Market Segments
By Diagnosis
- Genetic Testing
- New-born Screening
- Other Diagnosis
By Treatment
- Nitrogen-Binding Adjunctive
- Nitrogen Scavenger Drugs
- Anti-Seizure Drugs
- Carbamazepine
- Oxcarbazepine
- Other Treatments
By End-User
- Hospitals
- Specialty Clinics
- Other End-Users
Growth Opportunity
Increasing Awareness and Diagnosis
The awareness of arginase deficiency among healthcare professionals and the general public has increased. Enhanced knowledge of the disease and its symptoms has led to an increase in the number of diagnoses, which is anticipated to stimulate market expansion.
Recent Advances in Genetic Testing
The advancement of genetic testing techniques has facilitated the accurate diagnosis of arginase deficiency. These tests help identify the genetic mutations that cause the disorder, allowing for early intervention and treatment. It is anticipated that the availability of dependable and cost-effective genetic testing methods will contribute to market expansion.
Emerging Therapeutic Approaches
For arginase deficiency, scientists and pharmaceutical companies are actively developing novel therapeutic approaches. This includes exploring gene therapy, enzyme replacement therapy, and small molecule inhibitors to restore the urea cycle and lower ammonia levels within the body. These innovative treatment options are anticipated to drive market expansion by providing patients with superior management options.
The Orphan Drug Designation
Arginase deficiency is a rare disease, and several countries have designated potential treatments as orphan drugs. This designation provides pharmaceutical companies with incentives, including market exclusivity, tax credits, and reduced regulatory requirements. These incentives encourage investment in research and development, which leads to the creation of new therapies and market expansion.
Increasing Healthcare Expenditures
The rise in global healthcare spending is anticipated to have a positive effect on the arginase deficiency market. Governments and private organizations are allocating more funds to rare diseases, such as arginase deficiency, in order to enhance patient care and support research and development initiatives. By facilitating the development and commercialization of new therapies, this increased funding is likely to stimulate market expansion.
Latest Trends
Disease Management Approaches
In recent years, arginase deficiency disease management has endured significant changes. The standard treatment for arginase deficiency has been a low-protein diet supplemented with arginine. This strategy attempts to reduce the accumulation of arginine in the body and treat the disease's symptoms. However, this approach has not been very effective in treating the neurological symptoms of the disease.
The most recent method for treating arginase deficiency focuses on enhancing the body's arginine metabolism. This strategy entails the use of arginine-metabolizing drugs, such as nitric oxide (NO) donors and arginine ester compounds. It has been demonstrated that these medications alleviate the neurological symptoms of arginase deficiency.
Therapeutic Dietary Interventions
Dietary interventions are also essential in the management of arginase deficiency. For many years, a low-protein diet with arginine supplementation has been the standard treatment for arginase deficiency. This strategy has limitations, as it can be difficult to maintain a low-protein diet for an extended period of time.
The use of medical foods, which are specially formulated foods designed to manage the nutritional requirements of patients with arginase deficiency, is a more recent approach to dietary interventions. These foods are designed to alleviate the symptoms of arginase deficiency while supplying the patient with essential nutrients.
Gene Therapies
Emerging in the treatment of arginase deficiency are gene therapies. The defective gene responsible for arginase deficiency is replaced by a functional gene delivered to the patient's cells through gene therapy.
Several gene therapy approaches for arginase deficiency are in development. The delivery of the functional arginase gene to the liver, where it can produce the enzyme required to metabolize arginine, is one approach. Small interfering RNA (siRNA), which can suppress the expression of the defective gene responsible for arginase deficiency, is another approach.
Precision Medicine Integration
The integration of precision medicine is a recent development in the treatment of arginase deficiency. Precision medicine involves the utilization of personalized treatment plans based on the genetics, environment, and lifestyle of the patient.
Incorporating precision medicine into the treatment of arginase deficiency requires genetic testing to identify the disease-causing mutation in each patient's gene. This information is then used to develop an individualized treatment plan based on the patient's specific requirements.
Regional Analysis
The Arginase Deficiency Market is dominated by Europe. Europe is home to the world's foremost medical centers, research institutions, and specialists in healthcare with knowledge of uncommon diseases. These centers frequently collaborate with pharmaceutical companies and conduct clinical trials, which contributes to advances in arginase deficiency research and treatment. Europe's concentration of expertise can contribute to the development of innovative therapies and attract investment to the continent.
Europe has a well-established regulatory framework for orphan pharmaceuticals that includes incentives and streamlined commercialization processes. The European Medicines Agency (EMA) provides the Orphan Medicinal Product Designation, which provides companies with advantages including market exclusivity, reduced fees, and scientific advice. These regulations encourage pharmaceutical companies to concentrate on rare diseases, such as arginase deficiency, and foster market expansion.
Patients with rare diseases have access to healthcare services in numerous European nations with universal healthcare systems or robust insurance coverage. This accessibility encourages early diagnosis, regular monitoring, and proper management of arginase deficiency, thereby propelling market expansion.
Frequently, European nations allot substantial funds to research and development in the healthcare industry, including uncommon diseases. Researchers, institutions, and pharmaceutical companies have access to a variety of funding programs and initiatives that can foster advancements in the understanding and treatment of arginase deficiency.
Several patient advocacy organizations in Europe are devoted to uncommon diseases, such as arginase deficiency. These organizations play an essential role in raising awareness, assisting patients and their families, and advocating for better treatments and resources. Their efforts can lead to an increase in research funding and collaborations, thereby enhancing Europe's market position in the arginase deficiency field.
Key Regions and Countries
North America
- US
- Canada
- Mexico
Western Europe
- Germany
- France
- The UK
- Spain
- Italy
- Portugal
- Ireland
- Austria
- Switzerland
- Benelux
- Nordic
- Rest of Western Europe
Eastern Europe
- Russia
- Poland
- The Czech Republic
- Greece
- Rest of Eastern Europe
APAC
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- Indonesia
- Malaysia
- Philippines
- Singapore
- Thailand
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Colombia
- Chile
- Argentina
- Costa Rica
- Rest of Latin America
Middle East & Africa
- Algeria
- Egypt
- Israel
- Kuwait
- Nigeria
- Saudi Arabia
- South Africa
- Turkey
- United Arab Emirates
- Rest of MEA
Key Players Analysis
Novartis is one of the leading companies in the arginase deficiency market, with N-carbamyl-L-glutamic acid (Carglumic Acid) serving as a treatment option for patients with urea cycle disorders. N-carbamyl-L-glutamic acid replenishes the urea cycle, allowing patients to remove excess nitrogen from their bodies efficiently.
Codexis, Inc. is an additional significant player in this market. They are developing CDX-6114, an engineered version of the arginase enzyme, as a novel enzyme therapy. This treatment modality seeks to enhance arginine metabolism in patients with arginase deficiency, thereby normalizing blood ammonia levels.
Horizon Therapeutics is also a prominent player in this market, with their Ravicti (glycerol phenylbutyrate) product, which is used to treat patients with urea cycle disorders. Ravicti enables patients to eliminate excess nitrogen through alternative pathways, thereby reducing deleterious accumulation in their bodies.
Top Key Players in Arginase Deficiency Market
- Novartis
- Codexis Inc
- Horizon Therapeutics
- Aeglea BioTherapeutics
- Orphan Technologies Ltd.
- Adverum Biotechnologies Inc.
- Moderna Therapeutics
- Roche Applied Science
- Thermo Fisher Scientific
- Abcam
- Alfa Wassermann Diagnostic Technologies
- Other Key Players
Recent Development
- In 2021, the FDA approved the first gene therapy for treating the rare genetic condition. This breakthrough represents a significant milestone for patients suffering from arginase deficiency, a condition characterized by the accumulation of toxic substances in the body and severe impairment of neurological and cognitive function.
- In 2022, a new clinical trial was initiated to evaluate the efficacy of a small molecule drug for arginase deficiency, which was another promising development. Targeting the metabolic pathway responsible for the accumulation of toxic substances in the body, this drug seeks to alleviate the symptoms of the disease.
Report Scope
Report Features Description Market Value (2022) USD 102 Mn Forecast Revenue (2032) USD 152.3 Mn CAGR (2023-2032) 4.2% Base Year for Estimation 2022 Historic Period 2016-2022 Forecast Period 2023-2032 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered By Diagnosis (Genetic Testing, New-born Screening, And Others)
By Treatment (Nitrogen-Binding Adjunctive, Nitrogen Scavenger Drugs, Anti-Seizure Drugs, Carbamazepine, Oxcarbazepine, And Others)
By End-User (Hospitals, Specialty Clinics, And Others)Regional Analysis North America – The US, Canada, & Mexico; Western Europe – Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, & Rest of Western Europe; Eastern Europe – Russia, Poland, The Czech Republic, Greece, & Rest of Eastern Europe; APAC – China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, & Rest of APAC; Latin America – Brazil, Colombia, Chile, Argentina, Costa Rica, & Rest of Latin America; the Middle East & Africa – Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, & Rest of MEA Competitive Landscape Novartis, Codexis Inc, Horizon Therapeutics, Aeglea BioTherapeutics, Orphan Technologies Ltd., Adverum Biotechnologies Inc., Moderna Therapeutics, Roche Applied Science, Thermo Fisher Scientific, Abcam, Alfa Wassermann Diagnostic Technologies Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) -
- 1. Executive Summary
- 1.1. Definition
- 1.2. Taxonomy
- 1.3. Research Scope
- 1.4. Key Analysis
- 1.5. Key Findings by Major Segments
- 1.6. Top strategies by Major Players
- 2. Global Arginase Deficiency Market Overview
- 2.1. Arginase Deficiency Market Dynamics
- 2.1.1. Drivers
- 2.1.2. Opportunities
- 2.1.3. Restraints
- 2.1.4. Challenges
- 2.2. Macro-economic Factors
- 2.3. Regulatory Framework
- 2.4. Market Investment Feasibility Index
- 2.5. PEST Analysis
- 2.6. PORTER’S Five Force Analysis
- 2.7. Drivers & Restraints Impact Analysis
- 2.8. Industry Chain Analysis
- 2.9. Cost Structure Analysis
- 2.10. Marketing Strategy
- 2.11. Russia-Ukraine War Impact Analysis
- 2.12. Opportunity Map Analysis
- 2.13. Market Competition Scenario Analysis
- 2.14. Product Life Cycle Analysis
- 2.15. Opportunity Orbits
- 2.16. Manufacturer Intensity Map
- 2.17. Major Companies sales by Value & Volume
- 2.1. Arginase Deficiency Market Dynamics
- 3. Global Arginase Deficiency Market Analysis, Opportunity and Forecast, 2016-2032
- 3.1. Global Arginase Deficiency Market Analysis, 2016-2021
- 3.2. Global Arginase Deficiency Market Opportunity and Forecast, 2023-2032
- 3.3. Global Arginase Deficiency Market Analysis, Opportunity and Forecast, By By Diagnosis, 2016-2032
- 3.3.1. Global Arginase Deficiency Market Analysis by By Diagnosis: Introduction
- 3.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Diagnosis, 2016-2032
- 3.3.3. Genetic Testing
- 3.3.4. New-born Screening
- 3.4. Global Arginase Deficiency Market Analysis, Opportunity and Forecast, By By Treatment, 2016-2032
- 3.4.1. Global Arginase Deficiency Market Analysis by By Treatment: Introduction
- 3.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Treatment, 2016-2032
- 3.4.3. Nitrogen-Binding Adjunctive
- 3.4.4. Nitrogen Scavenger Drugs
- 3.4.5. Anti-Seizure Drugs
- 3.4.6. Carbamazepine
- 3.4.7. Oxcarbazepine
- 3.5. Global Arginase Deficiency Market Analysis, Opportunity and Forecast, By By End-User, 2016-2032
- 3.5.1. Global Arginase Deficiency Market Analysis by By End-User: Introduction
- 3.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By End-User, 2016-2032
- 3.5.3. Hospitals
- 3.5.4. Specialty Clinics
- 4. North America Arginase Deficiency Market Analysis, Opportunity and Forecast, 2016-2032
- 4.1. North America Arginase Deficiency Market Analysis, 2016-2021
- 4.2. North America Arginase Deficiency Market Opportunity and Forecast, 2023-2032
- 4.3. North America Arginase Deficiency Market Analysis, Opportunity and Forecast, By By Diagnosis, 2016-2032
- 4.3.1. North America Arginase Deficiency Market Analysis by By Diagnosis: Introduction
- 4.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Diagnosis, 2016-2032
- 4.3.3. Genetic Testing
- 4.3.4. New-born Screening
- 4.4. North America Arginase Deficiency Market Analysis, Opportunity and Forecast, By By Treatment, 2016-2032
- 4.4.1. North America Arginase Deficiency Market Analysis by By Treatment: Introduction
- 4.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Treatment, 2016-2032
- 4.4.3. Nitrogen-Binding Adjunctive
- 4.4.4. Nitrogen Scavenger Drugs
- 4.4.5. Anti-Seizure Drugs
- 4.4.6. Carbamazepine
- 4.4.7. Oxcarbazepine
- 4.5. North America Arginase Deficiency Market Analysis, Opportunity and Forecast, By By End-User, 2016-2032
- 4.5.1. North America Arginase Deficiency Market Analysis by By End-User: Introduction
- 4.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By End-User, 2016-2032
- 4.5.3. Hospitals
- 4.5.4. Specialty Clinics
- 4.6. North America Arginase Deficiency Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 4.6.1. North America Arginase Deficiency Market Analysis by Country : Introduction
- 4.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 4.6.2.1. The US
- 4.6.2.2. Canada
- 4.6.2.3. Mexico
- 5. Western Europe Arginase Deficiency Market Analysis, Opportunity and Forecast, 2016-2032
- 5.1. Western Europe Arginase Deficiency Market Analysis, 2016-2021
- 5.2. Western Europe Arginase Deficiency Market Opportunity and Forecast, 2023-2032
- 5.3. Western Europe Arginase Deficiency Market Analysis, Opportunity and Forecast, By By Diagnosis, 2016-2032
- 5.3.1. Western Europe Arginase Deficiency Market Analysis by By Diagnosis: Introduction
- 5.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Diagnosis, 2016-2032
- 5.3.3. Genetic Testing
- 5.3.4. New-born Screening
- 5.4. Western Europe Arginase Deficiency Market Analysis, Opportunity and Forecast, By By Treatment, 2016-2032
- 5.4.1. Western Europe Arginase Deficiency Market Analysis by By Treatment: Introduction
- 5.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Treatment, 2016-2032
- 5.4.3. Nitrogen-Binding Adjunctive
- 5.4.4. Nitrogen Scavenger Drugs
- 5.4.5. Anti-Seizure Drugs
- 5.4.6. Carbamazepine
- 5.4.7. Oxcarbazepine
- 5.5. Western Europe Arginase Deficiency Market Analysis, Opportunity and Forecast, By By End-User, 2016-2032
- 5.5.1. Western Europe Arginase Deficiency Market Analysis by By End-User: Introduction
- 5.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By End-User, 2016-2032
- 5.5.3. Hospitals
- 5.5.4. Specialty Clinics
- 5.6. Western Europe Arginase Deficiency Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 5.6.1. Western Europe Arginase Deficiency Market Analysis by Country : Introduction
- 5.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 5.6.2.1. Germany
- 5.6.2.2. France
- 5.6.2.3. The UK
- 5.6.2.4. Spain
- 5.6.2.5. Italy
- 5.6.2.6. Portugal
- 5.6.2.7. Ireland
- 5.6.2.8. Austria
- 5.6.2.9. Switzerland
- 5.6.2.10. Benelux
- 5.6.2.11. Nordic
- 5.6.2.12. Rest of Western Europe
- 6. Eastern Europe Arginase Deficiency Market Analysis, Opportunity and Forecast, 2016-2032
- 6.1. Eastern Europe Arginase Deficiency Market Analysis, 2016-2021
- 6.2. Eastern Europe Arginase Deficiency Market Opportunity and Forecast, 2023-2032
- 6.3. Eastern Europe Arginase Deficiency Market Analysis, Opportunity and Forecast, By By Diagnosis, 2016-2032
- 6.3.1. Eastern Europe Arginase Deficiency Market Analysis by By Diagnosis: Introduction
- 6.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Diagnosis, 2016-2032
- 6.3.3. Genetic Testing
- 6.3.4. New-born Screening
- 6.4. Eastern Europe Arginase Deficiency Market Analysis, Opportunity and Forecast, By By Treatment, 2016-2032
- 6.4.1. Eastern Europe Arginase Deficiency Market Analysis by By Treatment: Introduction
- 6.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Treatment, 2016-2032
- 6.4.3. Nitrogen-Binding Adjunctive
- 6.4.4. Nitrogen Scavenger Drugs
- 6.4.5. Anti-Seizure Drugs
- 6.4.6. Carbamazepine
- 6.4.7. Oxcarbazepine
- 6.5. Eastern Europe Arginase Deficiency Market Analysis, Opportunity and Forecast, By By End-User, 2016-2032
- 6.5.1. Eastern Europe Arginase Deficiency Market Analysis by By End-User: Introduction
- 6.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By End-User, 2016-2032
- 6.5.3. Hospitals
- 6.5.4. Specialty Clinics
- 6.6. Eastern Europe Arginase Deficiency Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 6.6.1. Eastern Europe Arginase Deficiency Market Analysis by Country : Introduction
- 6.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 6.6.2.1. Russia
- 6.6.2.2. Poland
- 6.6.2.3. The Czech Republic
- 6.6.2.4. Greece
- 6.6.2.5. Rest of Eastern Europe
- 7. APAC Arginase Deficiency Market Analysis, Opportunity and Forecast, 2016-2032
- 7.1. APAC Arginase Deficiency Market Analysis, 2016-2021
- 7.2. APAC Arginase Deficiency Market Opportunity and Forecast, 2023-2032
- 7.3. APAC Arginase Deficiency Market Analysis, Opportunity and Forecast, By By Diagnosis, 2016-2032
- 7.3.1. APAC Arginase Deficiency Market Analysis by By Diagnosis: Introduction
- 7.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Diagnosis, 2016-2032
- 7.3.3. Genetic Testing
- 7.3.4. New-born Screening
- 7.4. APAC Arginase Deficiency Market Analysis, Opportunity and Forecast, By By Treatment, 2016-2032
- 7.4.1. APAC Arginase Deficiency Market Analysis by By Treatment: Introduction
- 7.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Treatment, 2016-2032
- 7.4.3. Nitrogen-Binding Adjunctive
- 7.4.4. Nitrogen Scavenger Drugs
- 7.4.5. Anti-Seizure Drugs
- 7.4.6. Carbamazepine
- 7.4.7. Oxcarbazepine
- 7.5. APAC Arginase Deficiency Market Analysis, Opportunity and Forecast, By By End-User, 2016-2032
- 7.5.1. APAC Arginase Deficiency Market Analysis by By End-User: Introduction
- 7.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By End-User, 2016-2032
- 7.5.3. Hospitals
- 7.5.4. Specialty Clinics
- 7.6. APAC Arginase Deficiency Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 7.6.1. APAC Arginase Deficiency Market Analysis by Country : Introduction
- 7.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 7.6.2.1. China
- 7.6.2.2. Japan
- 7.6.2.3. South Korea
- 7.6.2.4. India
- 7.6.2.5. Australia & New Zeland
- 7.6.2.6. Indonesia
- 7.6.2.7. Malaysia
- 7.6.2.8. Philippines
- 7.6.2.9. Singapore
- 7.6.2.10. Thailand
- 7.6.2.11. Vietnam
- 7.6.2.12. Rest of APAC
- 8. Latin America Arginase Deficiency Market Analysis, Opportunity and Forecast, 2016-2032
- 8.1. Latin America Arginase Deficiency Market Analysis, 2016-2021
- 8.2. Latin America Arginase Deficiency Market Opportunity and Forecast, 2023-2032
- 8.3. Latin America Arginase Deficiency Market Analysis, Opportunity and Forecast, By By Diagnosis, 2016-2032
- 8.3.1. Latin America Arginase Deficiency Market Analysis by By Diagnosis: Introduction
- 8.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Diagnosis, 2016-2032
- 8.3.3. Genetic Testing
- 8.3.4. New-born Screening
- 8.4. Latin America Arginase Deficiency Market Analysis, Opportunity and Forecast, By By Treatment, 2016-2032
- 8.4.1. Latin America Arginase Deficiency Market Analysis by By Treatment: Introduction
- 8.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Treatment, 2016-2032
- 8.4.3. Nitrogen-Binding Adjunctive
- 8.4.4. Nitrogen Scavenger Drugs
- 8.4.5. Anti-Seizure Drugs
- 8.4.6. Carbamazepine
- 8.4.7. Oxcarbazepine
- 8.5. Latin America Arginase Deficiency Market Analysis, Opportunity and Forecast, By By End-User, 2016-2032
- 8.5.1. Latin America Arginase Deficiency Market Analysis by By End-User: Introduction
- 8.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By End-User, 2016-2032
- 8.5.3. Hospitals
- 8.5.4. Specialty Clinics
- 8.6. Latin America Arginase Deficiency Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 8.6.1. Latin America Arginase Deficiency Market Analysis by Country : Introduction
- 8.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 8.6.2.1. Brazil
- 8.6.2.2. Colombia
- 8.6.2.3. Chile
- 8.6.2.4. Argentina
- 8.6.2.5. Costa Rica
- 8.6.2.6. Rest of Latin America
- 9. Middle East & Africa Arginase Deficiency Market Analysis, Opportunity and Forecast, 2016-2032
- 9.1. Middle East & Africa Arginase Deficiency Market Analysis, 2016-2021
- 9.2. Middle East & Africa Arginase Deficiency Market Opportunity and Forecast, 2023-2032
- 9.3. Middle East & Africa Arginase Deficiency Market Analysis, Opportunity and Forecast, By By Diagnosis, 2016-2032
- 9.3.1. Middle East & Africa Arginase Deficiency Market Analysis by By Diagnosis: Introduction
- 9.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Diagnosis, 2016-2032
- 9.3.3. Genetic Testing
- 9.3.4. New-born Screening
- 9.4. Middle East & Africa Arginase Deficiency Market Analysis, Opportunity and Forecast, By By Treatment, 2016-2032
- 9.4.1. Middle East & Africa Arginase Deficiency Market Analysis by By Treatment: Introduction
- 9.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Treatment, 2016-2032
- 9.4.3. Nitrogen-Binding Adjunctive
- 9.4.4. Nitrogen Scavenger Drugs
- 9.4.5. Anti-Seizure Drugs
- 9.4.6. Carbamazepine
- 9.4.7. Oxcarbazepine
- 9.5. Middle East & Africa Arginase Deficiency Market Analysis, Opportunity and Forecast, By By End-User, 2016-2032
- 9.5.1. Middle East & Africa Arginase Deficiency Market Analysis by By End-User: Introduction
- 9.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By End-User, 2016-2032
- 9.5.3. Hospitals
- 9.5.4. Specialty Clinics
- 9.6. Middle East & Africa Arginase Deficiency Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 9.6.1. Middle East & Africa Arginase Deficiency Market Analysis by Country : Introduction
- 9.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 9.6.2.1. Algeria
- 9.6.2.2. Egypt
- 9.6.2.3. Israel
- 9.6.2.4. Kuwait
- 9.6.2.5. Nigeria
- 9.6.2.6. Saudi Arabia
- 9.6.2.7. South Africa
- 9.6.2.8. Turkey
- 9.6.2.9. The UAE
- 9.6.2.10. Rest of MEA
- 10. Global Arginase Deficiency Market Analysis, Opportunity and Forecast, By Region , 2016-2032
- 10.1. Global Arginase Deficiency Market Analysis by Region : Introduction
- 10.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Region , 2016-2032
- 10.2.1. North America
- 10.2.2. Western Europe
- 10.2.3. Eastern Europe
- 10.2.4. APAC
- 10.2.5. Latin America
- 10.2.6. Middle East & Africa
- 11. Global Arginase Deficiency Market Competitive Landscape, Market Share Analysis, and Company Profiles
- 11.1. Market Share Analysis
- 11.2. Company Profiles
- 11.3. Novartis
- 11.3.1. Company Overview
- 11.3.2. Financial Highlights
- 11.3.3. Product Portfolio
- 11.3.4. SWOT Analysis
- 11.3.5. Key Strategies and Developments
- 11.4. Codexis Inc
- 11.4.1. Company Overview
- 11.4.2. Financial Highlights
- 11.4.3. Product Portfolio
- 11.4.4. SWOT Analysis
- 11.4.5. Key Strategies and Developments
- 11.5. Horizon Therapeutics
- 11.5.1. Company Overview
- 11.5.2. Financial Highlights
- 11.5.3. Product Portfolio
- 11.5.4. SWOT Analysis
- 11.5.5. Key Strategies and Developments
- 11.6. Aeglea BioTherapeutics
- 11.6.1. Company Overview
- 11.6.2. Financial Highlights
- 11.6.3. Product Portfolio
- 11.6.4. SWOT Analysis
- 11.6.5. Key Strategies and Developments
- 11.7. Orphan Technologies Ltd.
- 11.7.1. Company Overview
- 11.7.2. Financial Highlights
- 11.7.3. Product Portfolio
- 11.7.4. SWOT Analysis
- 11.7.5. Key Strategies and Developments
- 11.8. Adverum Biotechnologies Inc.
- 11.8.1. Company Overview
- 11.8.2. Financial Highlights
- 11.8.3. Product Portfolio
- 11.8.4. SWOT Analysis
- 11.8.5. Key Strategies and Developments
- 11.9. Moderna Therapeutics
- 11.9.1. Company Overview
- 11.9.2. Financial Highlights
- 11.9.3. Product Portfolio
- 11.9.4. SWOT Analysis
- 11.9.5. Key Strategies and Developments
- 11.10. Roche Applied Science
- 11.10.1. Company Overview
- 11.10.2. Financial Highlights
- 11.10.3. Product Portfolio
- 11.10.4. SWOT Analysis
- 11.10.5. Key Strategies and Developments
- 11.11. Thermo Fisher Scientific
- 11.11.1. Company Overview
- 11.11.2. Financial Highlights
- 11.11.3. Product Portfolio
- 11.11.4. SWOT Analysis
- 11.11.5. Key Strategies and Developments
- 11.12. Abcam
- 11.12.1. Company Overview
- 11.12.2. Financial Highlights
- 11.12.3. Product Portfolio
- 11.12.4. SWOT Analysis
- 11.12.5. Key Strategies and Developments
- 11.13. Alfa Wassermann Diagnostic Technologies
- 11.13.1. Company Overview
- 11.13.2. Financial Highlights
- 11.13.3. Product Portfolio
- 11.13.4. SWOT Analysis
- 11.13.5. Key Strategies and Developments
- 12. Assumptions and Acronyms
- 13. Research Methodology
- 14. Contact
List of Figures
- Figure 1: Global Arginase Deficiency Market Revenue (US$ Mn) Market Share by By Diagnosis in 2022
- Figure 2: Global Arginase Deficiency Market Attractiveness Analysis by By Diagnosis, 2016-2032
- Figure 3: Global Arginase Deficiency Market Revenue (US$ Mn) Market Share by By Treatmentin 2022
- Figure 4: Global Arginase Deficiency Market Attractiveness Analysis by By Treatment, 2016-2032
- Figure 5: Global Arginase Deficiency Market Revenue (US$ Mn) Market Share by By End-Userin 2022
- Figure 6: Global Arginase Deficiency Market Attractiveness Analysis by By End-User, 2016-2032
- Figure 7: Global Arginase Deficiency Market Revenue (US$ Mn) Market Share by Region in 2022
- Figure 8: Global Arginase Deficiency Market Attractiveness Analysis by Region, 2016-2032
- Figure 9: Global Arginase Deficiency Market Revenue (US$ Mn) (2016-2032)
- Figure 10: Global Arginase Deficiency Market Revenue (US$ Mn) Comparison by Region (2016-2032)
- Figure 11: Global Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Diagnosis (2016-2032)
- Figure 12: Global Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Figure 13: Global Arginase Deficiency Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Figure 14: Global Arginase Deficiency Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
- Figure 15: Global Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Diagnosis (2016-2032)
- Figure 16: Global Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Figure 17: Global Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Figure 18: Global Arginase Deficiency Market Share Comparison by Region (2016-2032)
- Figure 19: Global Arginase Deficiency Market Share Comparison by By Diagnosis (2016-2032)
- Figure 20: Global Arginase Deficiency Market Share Comparison by By Treatment (2016-2032)
- Figure 21: Global Arginase Deficiency Market Share Comparison by By End-User (2016-2032)
- Figure 22: North America Arginase Deficiency Market Revenue (US$ Mn) Market Share by By Diagnosisin 2022
- Figure 23: North America Arginase Deficiency Market Attractiveness Analysis by By Diagnosis, 2016-2032
- Figure 24: North America Arginase Deficiency Market Revenue (US$ Mn) Market Share by By Treatmentin 2022
- Figure 25: North America Arginase Deficiency Market Attractiveness Analysis by By Treatment, 2016-2032
- Figure 26: North America Arginase Deficiency Market Revenue (US$ Mn) Market Share by By End-Userin 2022
- Figure 27: North America Arginase Deficiency Market Attractiveness Analysis by By End-User, 2016-2032
- Figure 28: North America Arginase Deficiency Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 29: North America Arginase Deficiency Market Attractiveness Analysis by Country, 2016-2032
- Figure 30: North America Arginase Deficiency Market Revenue (US$ Mn) (2016-2032)
- Figure 31: North America Arginase Deficiency Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 32: North America Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Diagnosis (2016-2032)
- Figure 33: North America Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Figure 34: North America Arginase Deficiency Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Figure 35: North America Arginase Deficiency Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 36: North America Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Diagnosis (2016-2032)
- Figure 37: North America Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Figure 38: North America Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Figure 39: North America Arginase Deficiency Market Share Comparison by Country (2016-2032)
- Figure 40: North America Arginase Deficiency Market Share Comparison by By Diagnosis (2016-2032)
- Figure 41: North America Arginase Deficiency Market Share Comparison by By Treatment (2016-2032)
- Figure 42: North America Arginase Deficiency Market Share Comparison by By End-User (2016-2032)
- Figure 43: Western Europe Arginase Deficiency Market Revenue (US$ Mn) Market Share by By Diagnosisin 2022
- Figure 44: Western Europe Arginase Deficiency Market Attractiveness Analysis by By Diagnosis, 2016-2032
- Figure 45: Western Europe Arginase Deficiency Market Revenue (US$ Mn) Market Share by By Treatmentin 2022
- Figure 46: Western Europe Arginase Deficiency Market Attractiveness Analysis by By Treatment, 2016-2032
- Figure 47: Western Europe Arginase Deficiency Market Revenue (US$ Mn) Market Share by By End-Userin 2022
- Figure 48: Western Europe Arginase Deficiency Market Attractiveness Analysis by By End-User, 2016-2032
- Figure 49: Western Europe Arginase Deficiency Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 50: Western Europe Arginase Deficiency Market Attractiveness Analysis by Country, 2016-2032
- Figure 51: Western Europe Arginase Deficiency Market Revenue (US$ Mn) (2016-2032)
- Figure 52: Western Europe Arginase Deficiency Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 53: Western Europe Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Diagnosis (2016-2032)
- Figure 54: Western Europe Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Figure 55: Western Europe Arginase Deficiency Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Figure 56: Western Europe Arginase Deficiency Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 57: Western Europe Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Diagnosis (2016-2032)
- Figure 58: Western Europe Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Figure 59: Western Europe Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Figure 60: Western Europe Arginase Deficiency Market Share Comparison by Country (2016-2032)
- Figure 61: Western Europe Arginase Deficiency Market Share Comparison by By Diagnosis (2016-2032)
- Figure 62: Western Europe Arginase Deficiency Market Share Comparison by By Treatment (2016-2032)
- Figure 63: Western Europe Arginase Deficiency Market Share Comparison by By End-User (2016-2032)
- Figure 64: Eastern Europe Arginase Deficiency Market Revenue (US$ Mn) Market Share by By Diagnosisin 2022
- Figure 65: Eastern Europe Arginase Deficiency Market Attractiveness Analysis by By Diagnosis, 2016-2032
- Figure 66: Eastern Europe Arginase Deficiency Market Revenue (US$ Mn) Market Share by By Treatmentin 2022
- Figure 67: Eastern Europe Arginase Deficiency Market Attractiveness Analysis by By Treatment, 2016-2032
- Figure 68: Eastern Europe Arginase Deficiency Market Revenue (US$ Mn) Market Share by By End-Userin 2022
- Figure 69: Eastern Europe Arginase Deficiency Market Attractiveness Analysis by By End-User, 2016-2032
- Figure 70: Eastern Europe Arginase Deficiency Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 71: Eastern Europe Arginase Deficiency Market Attractiveness Analysis by Country, 2016-2032
- Figure 72: Eastern Europe Arginase Deficiency Market Revenue (US$ Mn) (2016-2032)
- Figure 73: Eastern Europe Arginase Deficiency Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 74: Eastern Europe Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Diagnosis (2016-2032)
- Figure 75: Eastern Europe Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Figure 76: Eastern Europe Arginase Deficiency Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Figure 77: Eastern Europe Arginase Deficiency Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 78: Eastern Europe Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Diagnosis (2016-2032)
- Figure 79: Eastern Europe Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Figure 80: Eastern Europe Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Figure 81: Eastern Europe Arginase Deficiency Market Share Comparison by Country (2016-2032)
- Figure 82: Eastern Europe Arginase Deficiency Market Share Comparison by By Diagnosis (2016-2032)
- Figure 83: Eastern Europe Arginase Deficiency Market Share Comparison by By Treatment (2016-2032)
- Figure 84: Eastern Europe Arginase Deficiency Market Share Comparison by By End-User (2016-2032)
- Figure 85: APAC Arginase Deficiency Market Revenue (US$ Mn) Market Share by By Diagnosisin 2022
- Figure 86: APAC Arginase Deficiency Market Attractiveness Analysis by By Diagnosis, 2016-2032
- Figure 87: APAC Arginase Deficiency Market Revenue (US$ Mn) Market Share by By Treatmentin 2022
- Figure 88: APAC Arginase Deficiency Market Attractiveness Analysis by By Treatment, 2016-2032
- Figure 89: APAC Arginase Deficiency Market Revenue (US$ Mn) Market Share by By End-Userin 2022
- Figure 90: APAC Arginase Deficiency Market Attractiveness Analysis by By End-User, 2016-2032
- Figure 91: APAC Arginase Deficiency Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 92: APAC Arginase Deficiency Market Attractiveness Analysis by Country, 2016-2032
- Figure 93: APAC Arginase Deficiency Market Revenue (US$ Mn) (2016-2032)
- Figure 94: APAC Arginase Deficiency Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 95: APAC Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Diagnosis (2016-2032)
- Figure 96: APAC Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Figure 97: APAC Arginase Deficiency Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Figure 98: APAC Arginase Deficiency Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 99: APAC Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Diagnosis (2016-2032)
- Figure 100: APAC Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Figure 101: APAC Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Figure 102: APAC Arginase Deficiency Market Share Comparison by Country (2016-2032)
- Figure 103: APAC Arginase Deficiency Market Share Comparison by By Diagnosis (2016-2032)
- Figure 104: APAC Arginase Deficiency Market Share Comparison by By Treatment (2016-2032)
- Figure 105: APAC Arginase Deficiency Market Share Comparison by By End-User (2016-2032)
- Figure 106: Latin America Arginase Deficiency Market Revenue (US$ Mn) Market Share by By Diagnosisin 2022
- Figure 107: Latin America Arginase Deficiency Market Attractiveness Analysis by By Diagnosis, 2016-2032
- Figure 108: Latin America Arginase Deficiency Market Revenue (US$ Mn) Market Share by By Treatmentin 2022
- Figure 109: Latin America Arginase Deficiency Market Attractiveness Analysis by By Treatment, 2016-2032
- Figure 110: Latin America Arginase Deficiency Market Revenue (US$ Mn) Market Share by By End-Userin 2022
- Figure 111: Latin America Arginase Deficiency Market Attractiveness Analysis by By End-User, 2016-2032
- Figure 112: Latin America Arginase Deficiency Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 113: Latin America Arginase Deficiency Market Attractiveness Analysis by Country, 2016-2032
- Figure 114: Latin America Arginase Deficiency Market Revenue (US$ Mn) (2016-2032)
- Figure 115: Latin America Arginase Deficiency Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 116: Latin America Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Diagnosis (2016-2032)
- Figure 117: Latin America Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Figure 118: Latin America Arginase Deficiency Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Figure 119: Latin America Arginase Deficiency Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 120: Latin America Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Diagnosis (2016-2032)
- Figure 121: Latin America Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Figure 122: Latin America Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Figure 123: Latin America Arginase Deficiency Market Share Comparison by Country (2016-2032)
- Figure 124: Latin America Arginase Deficiency Market Share Comparison by By Diagnosis (2016-2032)
- Figure 125: Latin America Arginase Deficiency Market Share Comparison by By Treatment (2016-2032)
- Figure 126: Latin America Arginase Deficiency Market Share Comparison by By End-User (2016-2032)
- Figure 127: Middle East & Africa Arginase Deficiency Market Revenue (US$ Mn) Market Share by By Diagnosisin 2022
- Figure 128: Middle East & Africa Arginase Deficiency Market Attractiveness Analysis by By Diagnosis, 2016-2032
- Figure 129: Middle East & Africa Arginase Deficiency Market Revenue (US$ Mn) Market Share by By Treatmentin 2022
- Figure 130: Middle East & Africa Arginase Deficiency Market Attractiveness Analysis by By Treatment, 2016-2032
- Figure 131: Middle East & Africa Arginase Deficiency Market Revenue (US$ Mn) Market Share by By End-Userin 2022
- Figure 132: Middle East & Africa Arginase Deficiency Market Attractiveness Analysis by By End-User, 2016-2032
- Figure 133: Middle East & Africa Arginase Deficiency Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 134: Middle East & Africa Arginase Deficiency Market Attractiveness Analysis by Country, 2016-2032
- Figure 135: Middle East & Africa Arginase Deficiency Market Revenue (US$ Mn) (2016-2032)
- Figure 136: Middle East & Africa Arginase Deficiency Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 137: Middle East & Africa Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Diagnosis (2016-2032)
- Figure 138: Middle East & Africa Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Figure 139: Middle East & Africa Arginase Deficiency Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Figure 140: Middle East & Africa Arginase Deficiency Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 141: Middle East & Africa Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Diagnosis (2016-2032)
- Figure 142: Middle East & Africa Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Figure 143: Middle East & Africa Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Figure 144: Middle East & Africa Arginase Deficiency Market Share Comparison by Country (2016-2032)
- Figure 145: Middle East & Africa Arginase Deficiency Market Share Comparison by By Diagnosis (2016-2032)
- Figure 146: Middle East & Africa Arginase Deficiency Market Share Comparison by By Treatment (2016-2032)
- Figure 147: Middle East & Africa Arginase Deficiency Market Share Comparison by By End-User (2016-2032)
List of Tables
- Table 1: Global Arginase Deficiency Market Comparison by By Diagnosis (2016-2032)
- Table 2: Global Arginase Deficiency Market Comparison by By Treatment (2016-2032)
- Table 3: Global Arginase Deficiency Market Comparison by By End-User (2016-2032)
- Table 4: Global Arginase Deficiency Market Revenue (US$ Mn) Comparison by Region (2016-2032)
- Table 5: Global Arginase Deficiency Market Revenue (US$ Mn) (2016-2032)
- Table 6: Global Arginase Deficiency Market Revenue (US$ Mn) Comparison by Region (2016-2032)
- Table 7: Global Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Diagnosis (2016-2032)
- Table 8: Global Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Table 9: Global Arginase Deficiency Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Table 10: Global Arginase Deficiency Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
- Table 11: Global Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Diagnosis (2016-2032)
- Table 12: Global Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Table 13: Global Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Table 14: Global Arginase Deficiency Market Share Comparison by Region (2016-2032)
- Table 15: Global Arginase Deficiency Market Share Comparison by By Diagnosis (2016-2032)
- Table 16: Global Arginase Deficiency Market Share Comparison by By Treatment (2016-2032)
- Table 17: Global Arginase Deficiency Market Share Comparison by By End-User (2016-2032)
- Table 18: North America Arginase Deficiency Market Comparison by By Treatment (2016-2032)
- Table 19: North America Arginase Deficiency Market Comparison by By End-User (2016-2032)
- Table 20: North America Arginase Deficiency Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 21: North America Arginase Deficiency Market Revenue (US$ Mn) (2016-2032)
- Table 22: North America Arginase Deficiency Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 23: North America Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Diagnosis (2016-2032)
- Table 24: North America Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Table 25: North America Arginase Deficiency Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Table 26: North America Arginase Deficiency Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 27: North America Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Diagnosis (2016-2032)
- Table 28: North America Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Table 29: North America Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Table 30: North America Arginase Deficiency Market Share Comparison by Country (2016-2032)
- Table 31: North America Arginase Deficiency Market Share Comparison by By Diagnosis (2016-2032)
- Table 32: North America Arginase Deficiency Market Share Comparison by By Treatment (2016-2032)
- Table 33: North America Arginase Deficiency Market Share Comparison by By End-User (2016-2032)
- Table 34: Western Europe Arginase Deficiency Market Comparison by By Diagnosis (2016-2032)
- Table 35: Western Europe Arginase Deficiency Market Comparison by By Treatment (2016-2032)
- Table 36: Western Europe Arginase Deficiency Market Comparison by By End-User (2016-2032)
- Table 37: Western Europe Arginase Deficiency Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 38: Western Europe Arginase Deficiency Market Revenue (US$ Mn) (2016-2032)
- Table 39: Western Europe Arginase Deficiency Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 40: Western Europe Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Diagnosis (2016-2032)
- Table 41: Western Europe Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Table 42: Western Europe Arginase Deficiency Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Table 43: Western Europe Arginase Deficiency Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 44: Western Europe Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Diagnosis (2016-2032)
- Table 45: Western Europe Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Table 46: Western Europe Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Table 47: Western Europe Arginase Deficiency Market Share Comparison by Country (2016-2032)
- Table 48: Western Europe Arginase Deficiency Market Share Comparison by By Diagnosis (2016-2032)
- Table 49: Western Europe Arginase Deficiency Market Share Comparison by By Treatment (2016-2032)
- Table 50: Western Europe Arginase Deficiency Market Share Comparison by By End-User (2016-2032)
- Table 51: Eastern Europe Arginase Deficiency Market Comparison by By Diagnosis (2016-2032)
- Table 52: Eastern Europe Arginase Deficiency Market Comparison by By Treatment (2016-2032)
- Table 53: Eastern Europe Arginase Deficiency Market Comparison by By End-User (2016-2032)
- Table 54: Eastern Europe Arginase Deficiency Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 55: Eastern Europe Arginase Deficiency Market Revenue (US$ Mn) (2016-2032)
- Table 56: Eastern Europe Arginase Deficiency Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 57: Eastern Europe Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Diagnosis (2016-2032)
- Table 58: Eastern Europe Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Table 59: Eastern Europe Arginase Deficiency Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Table 60: Eastern Europe Arginase Deficiency Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 61: Eastern Europe Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Diagnosis (2016-2032)
- Table 62: Eastern Europe Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Table 63: Eastern Europe Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Table 64: Eastern Europe Arginase Deficiency Market Share Comparison by Country (2016-2032)
- Table 65: Eastern Europe Arginase Deficiency Market Share Comparison by By Diagnosis (2016-2032)
- Table 66: Eastern Europe Arginase Deficiency Market Share Comparison by By Treatment (2016-2032)
- Table 67: Eastern Europe Arginase Deficiency Market Share Comparison by By End-User (2016-2032)
- Table 68: APAC Arginase Deficiency Market Comparison by By Diagnosis (2016-2032)
- Table 69: APAC Arginase Deficiency Market Comparison by By Treatment (2016-2032)
- Table 70: APAC Arginase Deficiency Market Comparison by By End-User (2016-2032)
- Table 71: APAC Arginase Deficiency Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 72: APAC Arginase Deficiency Market Revenue (US$ Mn) (2016-2032)
- Table 73: APAC Arginase Deficiency Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 74: APAC Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Diagnosis (2016-2032)
- Table 75: APAC Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Table 76: APAC Arginase Deficiency Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Table 77: APAC Arginase Deficiency Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 78: APAC Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Diagnosis (2016-2032)
- Table 79: APAC Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Table 80: APAC Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Table 81: APAC Arginase Deficiency Market Share Comparison by Country (2016-2032)
- Table 82: APAC Arginase Deficiency Market Share Comparison by By Diagnosis (2016-2032)
- Table 83: APAC Arginase Deficiency Market Share Comparison by By Treatment (2016-2032)
- Table 84: APAC Arginase Deficiency Market Share Comparison by By End-User (2016-2032)
- Table 85: Latin America Arginase Deficiency Market Comparison by By Diagnosis (2016-2032)
- Table 86: Latin America Arginase Deficiency Market Comparison by By Treatment (2016-2032)
- Table 87: Latin America Arginase Deficiency Market Comparison by By End-User (2016-2032)
- Table 88: Latin America Arginase Deficiency Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 89: Latin America Arginase Deficiency Market Revenue (US$ Mn) (2016-2032)
- Table 90: Latin America Arginase Deficiency Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 91: Latin America Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Diagnosis (2016-2032)
- Table 92: Latin America Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Table 93: Latin America Arginase Deficiency Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Table 94: Latin America Arginase Deficiency Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 95: Latin America Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Diagnosis (2016-2032)
- Table 96: Latin America Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Table 97: Latin America Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Table 98: Latin America Arginase Deficiency Market Share Comparison by Country (2016-2032)
- Table 99: Latin America Arginase Deficiency Market Share Comparison by By Diagnosis (2016-2032)
- Table 100: Latin America Arginase Deficiency Market Share Comparison by By Treatment (2016-2032)
- Table 101: Latin America Arginase Deficiency Market Share Comparison by By End-User (2016-2032)
- Table 102: Middle East & Africa Arginase Deficiency Market Comparison by By Diagnosis (2016-2032)
- Table 103: Middle East & Africa Arginase Deficiency Market Comparison by By Treatment (2016-2032)
- Table 104: Middle East & Africa Arginase Deficiency Market Comparison by By End-User (2016-2032)
- Table 105: Middle East & Africa Arginase Deficiency Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 106: Middle East & Africa Arginase Deficiency Market Revenue (US$ Mn) (2016-2032)
- Table 107: Middle East & Africa Arginase Deficiency Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 108: Middle East & Africa Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Diagnosis (2016-2032)
- Table 109: Middle East & Africa Arginase Deficiency Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Table 110: Middle East & Africa Arginase Deficiency Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Table 111: Middle East & Africa Arginase Deficiency Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 112: Middle East & Africa Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Diagnosis (2016-2032)
- Table 113: Middle East & Africa Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Table 114: Middle East & Africa Arginase Deficiency Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Table 115: Middle East & Africa Arginase Deficiency Market Share Comparison by Country (2016-2032)
- Table 116: Middle East & Africa Arginase Deficiency Market Share Comparison by By Diagnosis (2016-2032)
- Table 117: Middle East & Africa Arginase Deficiency Market Share Comparison by By Treatment (2016-2032)
- Table 118: Middle East & Africa Arginase Deficiency Market Share Comparison by By End-User (2016-2032)
- 1. Executive Summary
-
- Novartis
- Codexis Inc
- Horizon Therapeutics
- Aeglea BioTherapeutics
- Orphan Technologies Ltd.
- Adverum Biotechnologies Inc.
- Moderna Therapeutics
- Roche Applied Science
- Thermo Fisher Scientific
- Abcam
- Alfa Wassermann Diagnostic Technologies
- Other Key Players
Our Clients
View Our Licence Options
